This week APC's lawyers sent a formal comment to the FDA about Eli Lilly’s request that tirzepatide be added to the Demonstrably Difficult to Compound list. read more →
The California State Board of Pharmacy decided to move the modified proposed sterile compounding regulations forward to a 30-day comment period. read more →
If you haven’t already, don’t forget to download and share the 2023-2024 edition of our Snapshot of Pharmacy Compounding in America — a slick guide to the most important information and numbers that reflect the practice of pharmacy compounding in the US.
It’s perfect for sharing with policymakers, media, prescribers, and anyone else who could benefit from a primer on the practice.
The snapshot was made possible by the generous support of APC corporate patrons Fagron, Medisca, and PCCA.
